Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab in Healthy Chinese Subjects

NCT05045781 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05045781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05045781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab in Healthy Chinese Subjects
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
April 20, 2021
Completion date
July 20, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy